Menu
ncarol.com
  • Home
  • Education
  • Health
  • Technology
  • Books
  • Real Estate
  • Entertainment
  • Music
  • Book Release
ncarol.com

'Spot Detective' – Check your spots this summer
ncarol.com/10200678

Trending...
  • CCHR Report Links 145 Violent Incidents to Psychiatric Drug Exposure, Urges National Oversight and Action
  • Outlier Pest Season Hits Willamette Valley as Mild Winter Drives Early Surge in Ant and Rodent Activity
  • $10 Million Annual Revenue Merger, Profitable Partner in AI Powered Specialty Automotive Sales Projected to Scale Above $200M: Stock Symbol: NWPG
The Spot Detective - who are they The Spot Detective - freckle
The latest campaign urging Australians to get their skin checked

MELBOURNE, Australia & SYDNEY - ncarol.com -- OncoBeta, a leading medical device company specialising in innovative epidermal radioisotope therapies for non-melanoma skin cancer, has launched The Spot Detective campaign to rally Australians in the fight against skin cancer this summer.

With two out of three Australians diagnosed with skin cancer before the age of 701, it is vital for all Australians to have regular skin checks. The Spot Detective campaign is encouraging Australians to visit a Spot Detective – their GP, dermatologist or skin health specialist – to have their spots assessed and to learn about the various treatments available for those diagnosed with non-melanoma skin cancer.

Skin cancer occurs when skin cells are damaged, often from overexposure to ultraviolet (UV) radiation from the sun. There are three main types of skin cancer: basal cell carcinoma (BCC); squamous cell carcinoma (SCC) and melanoma.2 Australia has one of the highest melanoma rates in the world1, with one Australian dying from melanoma every six hours.3 A skin check can save your life.

OncoBeta's Australian Medical Director, Dr Sam Vohra, says, "Thankfully most skin cancers are treatable and most of us will know someone who has had a skin cancer. Today, there are a range of treatments available to patients in addition to surgery, some of which are painless*, only needing a single session† and non-invasive."4-6

The Spot Detective campaign is asking Australians to take action: if they see a skin spot that is suspicious, new, oddly shaped or has changed in colour then it's time to get it checked. The campaign includes a series of LIVE reads across 2GB and WSFM in Sydney and 3AW and Gold 104.3 in Melbourne, as well as a social media and digital marketing campaign, and free skin check pop-ups at various locations.

More on ncarol.com
  • Scott Ritsema of Bisnar Chase Selected for 2026 National Traumatic Brain Injury Association
  • Flint Youth Film Festival Shifts Gears, Becomes Vehicle City Film Festival
  • 62% of Gen X have no estate planning documents — Trust & Will research identifies "the Sandwich Gap"
  • Nayarit's Jungle Coast Redefines Luxury Travel on Mexico's Pacific Now More Accessible Than Ever
  • $10 Million Annual Revenue Merger, Profitable Partner in AI Powered Specialty Automotive Sales Projected to Scale Above $200M: Stock Symbol: NWPG

"With one of the highest incidences of skin cancer in the world, Australians need to be vigilant with their skin. The Spot Detective campaign is a timely reminder to make sure you are protecting yourself from the sun, and if you notice any changes to your skin, check in with a skin health specialist," added Dr Vohra.

Another health initiative from OncoBeta, this public awareness campaign also encourages anyone diagnosed with non-melanoma skin cancer to be well informed about all treatments and discuss their most suitable options with a healthcare professional. OncoBeta's skin cancer therapy which utilises the rhenium-188 isotope is now available at private clinics at Melbourne and Sydney. Patients with difficult anatomic localisations of a tumour, such as the ear, nose or anywhere on the face, and those with larger lesions problematic for plastic surgery, may benefit from this non-invasive solution.

To find out more information on skin cancer, and to learn what treatments are available, visit: www.spotdetective.com.au

About OncoBeta® GmbH
OncoBeta® GmbH, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.

Find out more about the Rhenium-SCT® at www.oncobeta.com

Follow us on social media:

More on ncarol.com
  • Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
  • Crankshooter Names Christian DiMonda Director of Marketing to Lead Brand Growth & Community Strategy
  • RAS AP Consulting Launches Vendor Master File & Payment Controls Assessment for NACHA Phase 2 Compliance
  • Living Waters Inc Announces the Passing of Founder and Former President & CEO Lawrence Barker-Bey, Jr
  • New Homesites Released at Heritage at Manalapan Featuring Scenic Golf Course Views

LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

*No reported pain.3
†
Complete tumour regression in 98.5% of lesions treated.

References:
1. Cancer Council. Understanding Skin Cancer. January 2020. https://www.cancercouncil.com.au/ (accessed October 2022).
2. Skin Cancer. Available at https://www.mayoclinic.org/diseases-conditions/skin-cancer/symptoms-causes/syc-20377605 [Accessed October 2022]
3. Melanoma Institute Australia. Melamoma Facts. https://melanoma.org.au/about-melanoma/melanoma-facts/ (accessed October 2022).
4. Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021; 48(5):1511–1521.
5. Cipriani C, et al. J Dermatol Treat. 2020; DOI: 10.1080/09546634.2020.1793890.
6. Cipriani C, et al. In Therapeutic Nuclear Medicine. 2014. RP Baum (Ed), New York: Springer.

Contact
Jane Morey
***@moreymedia.com.au


Source: OncoBeta GmbH
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Atelier 411 Studios and Columbus Fashion Council Present Red Carpet Experience at Gateway Film Center for The Devil Wears Prada 2
  • North Carolina Leadership Strategist Brings Real-World Solution
  • Hazel E Celebrates Birthday with Luxury "Goddess" Yacht Experience in Marina del Rey
  • SoPi Rugby's Taco Cook-Off (Cinco de Mayo Weekend)
  • Joseph Neibich sits down with Bold Jounrey (aka Joseph Nybyk)
  • Healing Hearts Home Care Hosts Peace of Mind Community Event
  • AI Suite 360 Launches Done-For-You AI Implementation to Rescue SMBs from the "Frankenstein Tax"
  • CX Network Releases Report on the Best AI Support Tools for SaaS Companies 2026
  • Outlier Pest Season Hits Willamette Valley as Mild Winter Drives Early Surge in Ant and Rodent Activity
  • Hinton Called for Maternal Instincts in AI; They're Ready for Testing with Anthropic's Mythos
  • Lokal Media House Wins Web Excellence Award for Black Plumbing Redesign
  • Charlotte Founder Launches Foot Odor Brand After Years of Embarrassment
  • Lick Expands Flavored Massage Oil Collection with 10 New Indulgent Cream-Inspired Scents
  • New from Regal House Publishing, Local Heroes, Lyric poems exploring themes drawn from ordinary life
  • New Research Identifies "Vacation Compatibility Gap" as the Hidden Force Shrinking How Long and With Whom Americans Travel
  • Melospeech Inc. Awarded New NYSDOH BEI Contract in New York
  • Five-star Review for Berklee School of Music Textbook
  • ZionSphere Launches Multi-Platform Virtual Reality Faith Experience Built from Rocky Mount, NC
  • Rocky Mount Founder Builds Virtual Reality Bible Experiences After Receiving Divine Directive
  • Advanced TeleSensors Appoints AgeTech Innovator Tiffany Wey, MBA as Vice President of Sales & Marketing
_catLbl0 _catLbl1

Popular on ncarol.com

  • UK Financial Ltd Launches UKFL Premier One as Its Official Broadcast Channel for Premium Content, Podcasts & Independent Expert Analysis - 112
  • Sycor Introduces Spring Release 2026 of Sycor.Rental with AI-Driven Innovations and Enhanced Service Processes
  • Advanced TeleSensors Appoints AgeTech Innovator Tiffany Wey, MBA as Vice President of Sales & Marketing
  • Pacific Emblem Company Launches "Happy 250th Birthday America" Collection and Proud Supporter of the Gary Sinise Foundation
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
  • Bold Beauty Project Celebrates Anniversary with Collaborative Exhibition at FIU's Miami Beach Urban Studios
  • Most Americans Choose Their Water Brand Because of Its Natural Source — Yet Fewer Than 3 in 10 Understand What Spring Water Actually Is
  • $112 Million Contract Backlog for Cycurion (N A S D A Q: CYCU) Enters Hyper-Growth Phase With, Strategic Acquisitions, & Exploding AI Cybersecurity
  • Everwild Music Festival Unveils 2026 Schedule: No Overlapping Sets, Longer Performances, and Epic Late-Night Sets!
  • Special Alert! Highly Undervalued Stock: $317M Revenue in 2025 for Telecom Leader IQSTEL, Inc. (N A S D A Q: IQST)

Similar on ncarol.com

  • Postmortem Pathology Opens Sacramento Office Offering Private Autopsies for Families and Healthcare Investigations
  • Postmortem Pathology, a leading provider of private autopsies, has announced its expansion into the Las Vegas market
  • Why Athletic Recovery Begins in the Nervous System
  • The Ultimate Solution to Halt Thermal Runaway
  • Strategic Talent Associates Launches THE ALIGNED RESET™
  • Karen D. Gentry Announces New Book Focused on Relationships and Personal Growth
  • New plusOne Research Finds the Orgasm Gap Is a 30-Point Chasm — and Confirms It Isn't Biology
  • CCHR Report Links 145 Violent Incidents to Psychiatric Drug Exposure, Urges National Oversight and Action
  • Healing Hearts Home Care Hosts Peace of Mind Community Event
  • CX Network Releases Report on the Best AI Support Tools for SaaS Companies 2026
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute